Amneal Pharmaceuticals, Class Stock Z Score

AMRX Stock

USD 8.62 0.13 1.49%

Altman Z Score is one of the simplest fundamental models to determine how likely your company is to fail. The module uses available fundamental data of a given equity to approximate the Altman Z score. Altman Z Score is determined by evaluating five fundamental price points available from the company's current public disclosure documents. Check out Amneal Pharmaceuticals, Piotroski F Score and Amneal Pharmaceuticals, Valuation analysis.

At this time, Amneal Pharmaceuticals,'s Capital Lease Obligations is fairly stable compared to the past year. Net Invested Capital is likely to rise to about 2.9 B in 2025, whereas Capital Surpluse is likely to drop slightly above 648.3 M in 2025. At this time, Amneal Pharmaceuticals,'s Research Development is fairly stable compared to the past year. Income Tax Expense is likely to rise to about 33.7 M in 2025, whereas Depreciation And Amortization is likely to drop slightly above 164.4 M in 2025.

Amneal Pharmaceuticals, Class Company Z Score Analysis

Amneal Pharmaceuticals,'s Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..

Z Score

Sum Of

5 Factors

More About Z Score | All Equity Analysis

First Factor

1.2 * (

Working Capital

/

Total Assets )

Second Factor

1.4 * (

Retained Earnings

/

Total Assets )

Thrid Factor

3.3 * (

EBITAD

/

Total Assets )

Fouth Factor

0.6 * (

Market Value of Equity

/

Total Liabilities )

Fifth Factor

0.99 * (

Revenue

/

Total Assets )

Amneal Z Score Driver Correlations

Understanding the fundamental principles of building solid financial models for Amneal Pharmaceuticals, is extremely important. It helps to project a fair market value of Amneal Stock properly, considering its historical fundamentals such as Z Score. Since Amneal Pharmaceuticals,'s main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Amneal Pharmaceuticals,'s historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Amneal Pharmaceuticals,'s interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Net Receivables	Good Will	Short Term Investments	Long Term Debt Total	Capital Surpluse	Total Liab	Short Long Term Debt	Total Current Assets	Treasury Stock	Short Term Debt	Intangible Assets	Common Stock	Property Plant Equipment	Current Deferred Revenue	Net Invested Capital	Net Working Capital	Capital Stock	Long Term Investments
Total Assets		0.83	-0.95	0.78	-0.34	0.7	0.91	0.83	0.92	-0.79	0.93	0.67	0.94	0.35	0.9	0.23	0.42	0.95	0.86	0.73	0.62	0.96	0.76	0.29	-0.2
Total Stockholder Equity	0.83		-0.78	0.75	0.18	0.77	0.74	0.5	0.64	-0.58	0.72	0.24	0.71	-0.11	0.64	-0.14	-0.05	0.9	0.55	0.59	0.17	0.8	0.83	-0.07	0.13
Net Tangible Assets	-0.95	-0.78		-0.83	0.47	-0.74	-0.98	-0.89	-0.94	0.9	-0.98	-0.73	-0.98	-0.44	-0.94	-0.26	-0.52	-0.97	-0.92	-0.87	-0.7	-0.99	-0.74	-0.37	0.26
Net Debt	0.78	0.75	-0.83		-0.2	0.53	0.86	0.68	0.76	-0.81	0.78	0.48	0.8	0.02	0.73	-0.25	0.18	0.83	0.61	0.73	0.44	0.81	0.8	-0.07	0.25
Retained Earnings	-0.34	0.18	0.47	-0.2		-0.12	-0.5	-0.7	-0.58	0.59	-0.53	-0.84	-0.55	-0.88	-0.59	-0.68	-0.91	-0.26	-0.7	-0.55	-0.85	-0.42	0.07	-0.71	0.65
Accounts Payable	0.7	0.77	-0.74	0.53	-0.12		0.66	0.48	0.54	-0.6	0.68	0.3	0.64	0.18	0.54	0.21	0.18	0.8	0.59	0.71	0.24	0.68	0.44	0.16	-0.18
Long Term Debt	0.91	0.74	-0.98	0.86	-0.5	0.66		0.92	0.94	-0.95	0.97	0.76	0.98	0.44	0.95	0.23	0.53	0.94	0.91	0.92	0.7	0.97	0.75	0.35	-0.24
Net Receivables	0.83	0.5	-0.89	0.68	-0.7	0.48	0.92		0.95	-0.88	0.95	0.93	0.95	0.61	0.97	0.48	0.68	0.8	0.92	0.85	0.86	0.88	0.58	0.45	-0.37
Good Will	0.92	0.64	-0.94	0.76	-0.58	0.54	0.94	0.95		-0.84	0.97	0.88	0.98	0.54	0.98	0.37	0.63	0.87	0.93	0.78	0.8	0.94	0.65	0.41	-0.29
Short Term Investments	-0.79	-0.58	0.9	-0.81	0.59	-0.6	-0.95	-0.88	-0.84		-0.9	-0.75	-0.91	-0.47	-0.89	-0.27	-0.55	-0.83	-0.85	-0.95	-0.7	-0.87	-0.65	-0.36	0.27
Long Term Debt Total	0.93	0.72	-0.98	0.78	-0.53	0.68	0.97	0.95	0.97	-0.9		0.83	0.99	0.5	0.98	0.37	0.57	0.93	0.92	0.88	0.74	0.96	0.68	0.36	-0.27
Capital Surpluse	0.67	0.24	-0.73	0.48	-0.84	0.3	0.76	0.93	0.88	-0.75	0.83		0.83	0.76	0.88	0.65	0.82	0.58	0.84	0.71	0.88	0.7	0.3	0.51	-0.45
Total Liab	0.94	0.71	-0.98	0.8	-0.55	0.64	0.98	0.95	0.98	-0.91	0.99	0.83		0.52	0.99	0.35	0.6	0.93	0.94	0.87	0.76	0.97	0.7	0.4	-0.3
Short Long Term Debt	0.35	-0.11	-0.44	0.02	-0.88	0.18	0.44	0.61	0.54	-0.47	0.5	0.76	0.52		0.57	0.83	0.98	0.26	0.72	0.48	0.68	0.41	-0.16	0.86	-0.84
Total Current Assets	0.9	0.64	-0.94	0.73	-0.59	0.54	0.95	0.97	0.98	-0.89	0.98	0.88	0.99	0.57		0.43	0.64	0.87	0.94	0.84	0.8	0.94	0.68	0.43	-0.35
Treasury Stock	0.23	-0.14	-0.26	-0.25	-0.68	0.21	0.23	0.48	0.37	-0.27	0.37	0.65	0.35	0.83	0.43		0.73	0.13	0.52	0.33	0.51	0.23	-0.23	0.66	-0.8
Short Term Debt	0.42	-0.05	-0.52	0.18	-0.91	0.18	0.53	0.68	0.63	-0.55	0.57	0.82	0.6	0.98	0.64	0.73		0.33	0.77	0.54	0.74	0.49	-0.07	0.8	-0.73
Intangible Assets	0.95	0.9	-0.97	0.83	-0.26	0.8	0.94	0.8	0.87	-0.83	0.93	0.58	0.93	0.26	0.87	0.13	0.33		0.84	0.81	0.55	0.97	0.81	0.25	-0.16
Common Stock	0.86	0.55	-0.92	0.61	-0.7	0.59	0.91	0.92	0.93	-0.85	0.92	0.84	0.94	0.72	0.94	0.52	0.77	0.84		0.82	0.83	0.92	0.52	0.68	-0.58
Property Plant Equipment	0.73	0.59	-0.87	0.73	-0.55	0.71	0.92	0.85	0.78	-0.95	0.88	0.71	0.87	0.48	0.84	0.33	0.54	0.81	0.82		0.62	0.82	0.55	0.36	-0.31
Current Deferred Revenue	0.62	0.17	-0.7	0.44	-0.85	0.24	0.7	0.86	0.8	-0.7	0.74	0.88	0.76	0.68	0.8	0.51	0.74	0.55	0.83	0.62		0.7	0.37	0.62	-0.52
Net Invested Capital	0.96	0.8	-0.99	0.81	-0.42	0.68	0.97	0.88	0.94	-0.87	0.96	0.7	0.97	0.41	0.94	0.23	0.49	0.97	0.92	0.82	0.7		0.78	0.41	-0.29
Net Working Capital	0.76	0.83	-0.74	0.8	0.07	0.44	0.75	0.58	0.65	-0.65	0.68	0.3	0.7	-0.16	0.68	-0.23	-0.07	0.81	0.52	0.55	0.37	0.78		-0.08	0.17
Capital Stock	0.29	-0.07	-0.37	-0.07	-0.71	0.16	0.35	0.45	0.41	-0.36	0.36	0.51	0.4	0.86	0.43	0.66	0.8	0.25	0.68	0.36	0.62	0.41	-0.08		-0.95
Long Term Investments	-0.2	0.13	0.26	0.25	0.65	-0.18	-0.24	-0.37	-0.29	0.27	-0.27	-0.45	-0.3	-0.84	-0.35	-0.8	-0.73	-0.16	-0.58	-0.31	-0.52	-0.29	0.17	-0.95

Click cells to compare fundamentals

To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.

Competition

Predict Amneal Pharmaceuticals,

In accordance with the company's disclosures, Amneal Pharmaceuticals, Class has a Z Score of 0.0. This is 100.0% lower than that of the Pharmaceuticals sector and about the same as Health Care (which currently averages 0.0) industry. The z score for all United States stocks is 100.0% higher than that of the company.

Amneal Z Score Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Amneal Pharmaceuticals,'s direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Amneal Pharmaceuticals, could also be used in its relative valuation, which is a method of valuing Amneal Pharmaceuticals, by comparing valuation metrics of similar companies.

Amneal Pharmaceuticals, is currently under evaluation in z score category among its peers.

Amneal Pharmaceuticals, ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Amneal Pharmaceuticals,'s sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Amneal Pharmaceuticals,'s managers, analysts, and investors.

Environmental

Governance

Social

Amneal Pharmaceuticals, Institutional Holders

Institutional Holdings refers to the ownership stake in Amneal Pharmaceuticals, that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Amneal Pharmaceuticals,'s outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Amneal Pharmaceuticals,'s value.

		Shares
Nuveen Asset Management, Llc	2024-12-31	2.7 M
Amvescap Plc.	2024-12-31	1.9 M
Northern Trust Corp	2024-12-31	1.8 M
Hennessy Advisors, Inc.	2024-12-31	1.7 M
Ubs Group Ag		1.7 M
Arrowstreet Capital Limited Partnership	2024-12-31	1.5 M
Charles Schwab Investment Management Inc	2024-12-31	1.5 M
Ameriprise Financial Inc	2024-12-31	1.5 M
Morgan Stanley - Brokerage Accounts	2024-12-31	1.5 M
Vanguard Group Inc	2024-12-31	14.8 M
Blackrock Inc	2024-12-31	12.6 M

Amneal Fundamentals

	Return On Equity	-8.81
	Return On Asset	0.0624
	Profit Margin	(0.04) %
	Operating Margin	0.11 %
	Current Valuation	5.19 B
	Shares Outstanding	309.97 M
	Shares Owned By Insiders	50.78 %
	Shares Owned By Institutions	41.67 %
	Number Of Shares Shorted	2.76 M
	Price To Earning	230.50 X
	Price To Book	86.10 X
	Price To Sales	1.43 X
	Revenue	2.79 B
	Gross Profit	1.02 B
	EBITDA	439.77 M
	Net Income	(73.88 M)
	Cash And Equivalents	87.33 M
	Cash Per Share	0.58 X
	Total Debt	331.35 M
	Current Ratio	1.74 X
	Book Value Per Share	(0.35) X
	Cash Flow From Operations	295.1 M
	Short Ratio	1.96 X
	Earnings Per Share	(0.38) X
	Price To Earnings To Growth	(0.30) X
	Target Price	11.5
	Number Of Employees	8.3 K
	Beta	1.05
	Market Capitalization	3.98 B
	Total Asset	3.5 B
	Retained Earnings	(607.06 M)
	Working Capital	458.04 M
	Current Asset	753.39 M
	Current Liabilities	310.2 M
	Net Asset	3.5 B

About Amneal Pharmaceuticals, Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Amneal Pharmaceuticals, Class's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Amneal Pharmaceuticals, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Amneal Pharmaceuticals, Class based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
CRM	Salesforce
CRM	Salesforce

Additional Tools for Amneal Stock Analysis

When running Amneal Pharmaceuticals,'s price analysis, check to measure Amneal Pharmaceuticals,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amneal Pharmaceuticals, is operating at the current time. Most of Amneal Pharmaceuticals,'s value examination focuses on studying past and present price action to predict the probability of Amneal Pharmaceuticals,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amneal Pharmaceuticals,'s price. Additionally, you may evaluate how the addition of Amneal Pharmaceuticals, to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Amneal Pharmaceuticals, Class Stock Z Score

Amneal Pharmaceuticals, Class Company Z Score Analysis

Z Score

Sum Of

5 Factors

First Factor

1.2 * (

Working Capital

/

Total Assets )

Second Factor

1.4 * (

Retained Earnings

/

Total Assets )

Thrid Factor

3.3 * (

EBITAD

/

Total Assets )

Fouth Factor

0.6 * (

Market Value of Equity

/

Total Liabilities )

Fifth Factor

0.99 * (

Revenue

/

Total Assets )

Amneal Z Score Driver Correlations

Amneal Z Score Peer Comparison

Amneal Pharmaceuticals, ESG Sustainability

Amneal Pharmaceuticals, Institutional Holders

Amneal Fundamentals

About Amneal Pharmaceuticals, Fundamental Analysis

Also Currently Popular

Additional Tools for Amneal Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY